KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Esperion Therapeutics (ESPR) Operating Expenses (2018 - 2025)

Esperion Therapeutics' Operating Expenses history spans 8 years, with the latest figure at -$130.4 million for Q4 2025.

  • For Q4 2025, Operating Expenses fell 277.37% year-over-year to -$130.4 million; the TTM value through Dec 2025 reached $129.2 million, down 53.5%, while the annual FY2025 figure was $129.2 million, 53.5% down from the prior year.
  • Operating Expenses reached -$130.4 million in Q4 2025 per ESPR's latest filing, down from $97.3 million in the prior quarter.
  • In the past five years, Operating Expenses ranged from a high of $97.3 million in Q3 2025 to a low of -$130.4 million in Q4 2025.
  • Average Operating Expenses over 5 years is $62.0 million, with a median of $71.1 million recorded in 2021.
  • The largest YoY upside for Operating Expenses was 43.76% in 2025 against a maximum downside of 277.37% in 2025.
  • A 5-year view of Operating Expenses shows it stood at $71.0 million in 2021, then fell by 13.65% to $61.3 million in 2022, then rose by 21.66% to $74.6 million in 2023, then dropped by 1.45% to $73.5 million in 2024, then tumbled by 277.37% to -$130.4 million in 2025.
  • Per Business Quant, the three most recent readings for ESPR's Operating Expenses are -$130.4 million (Q4 2025), $97.3 million (Q3 2025), and $75.3 million (Q2 2025).